Reports Q2 revenue $3.6M, consensus $3.54M. “We recorded record revenue of $3.6 million during the second quarter of 2023, an increase of 65% over the second quarter of 2022,” stated Dan Goldberger, Chief Executive Officer of electroCore. “This is our third consecutive quarter of significant sequential growth fueled by our prescription gammaCore business as well as our new products, Truvaga(TM), and TAC-STIM.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ECOR:
- electroCore Announces Second Quarter 2023 Financial Results
- electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
- electroCore to sell 1.68M shares at $4.4125 in registered direct offering
- electroCore announces publication of manuscript on VNS
- gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)